Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Mesothelioma, Malignant 1Mesothelioma 1Liver Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Imatinib Mesylate 71Sunitinib 31regorafenib 17nilotinib 15ripretinib 13avapritinib 7Laparoscopy 5Ipilimumab 5Dasatinib 5spartalizumab 4CTLA-4 Antigen 4Blood Specimen Collection 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Oxaliplatin 3Observation 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Biopsy 3Bevacizumab 3trametinib 2tanespimycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × alvocidib × Gastrointestinal × Clear all
NCT00098579 2013-03-19

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡